依达拉奉对慢性阻塞性肺疾病模型大鼠的干预作用

目的探讨依达拉奉在慢性阻塞性肺疾病(慢阻肺)的干预作用。方法取72只健康SD大鼠随机分为空白组、慢阻肺模型组、低剂量依达拉奉组和高剂量依达拉奉组,每组各18只,四组大鼠于造模4周后对肺功能、血清抗氧化因子、支气管肺泡灌洗液中炎性因子以及肺组织中金属蛋白酶水平进行检测和比较分析。结果肺功能检测结果显示,慢阻肺模型组与空白组相比,f、RI明显增高,Cdyn以及PIF水平均明显降低(P<0.05)。与慢阻肺模型组相比,低剂量依达拉奉组RI明显降低,Cdyn、PIF水平明显升高,高剂量依达拉奉组f、RI均明显降低,Cdyn及PIF明显升高。与低剂量依达拉奉组相比,高剂量依达拉奉组Cdyn明显升高(P<0.05)。血浆抗氧化物检测结果显示,与空白组相比,慢阻肺模型组MDA、SOD水平明显升高(P<0.05);与慢阻肺模型组相比,低剂量依达拉奉组和高剂量依达拉奉组MDA明显降低(P<0.05)。支气管肺泡灌洗液检测及结果显示,与空白组相比,慢阻肺模型组WBC、TNF-α水平明显升高(P<0.05);与慢阻肺模型组相比,低剂量依达拉奉组和高剂量依达拉奉组WBC、TNF-α水平均明显降低(P<0.05);与低剂量依达拉奉组相比,高剂量依达拉奉组WBC、TNF-α水平明显降低(P<0.05)。肺组织检测结果显示,与空白组相比,慢阻肺模型组MMP-9、MMP-12、Caspase-12、CHOP表达明显增强(P<0.05);与慢阻肺模型组相比,低剂量依达拉奉组和高剂量依达拉奉组MMP-9、MMP-12、Caspase-12、CHOP表达均明显减弱(P<0.05);与低剂量依达拉奉组相比,高剂量依达拉奉组MMP-9、MMP-12、Caspase-12、CHOP表达明显减弱(P<0.05)。结论依达拉奉可提高抗氧化能力、减少炎症因子的释放和聚集以及改善蛋白酶调节,对延缓慢阻肺临床病理进展有一定的作用。

Intervention effect of edaravone on chronic obstructive pulmonary disease in rats

Objective To discuss the intervention effect of edaravone on chronic obstructive pulmonary disease(COPD).Methods 72 healthy SD rats were randomly divided into the blank group,the COPD model group,the low dose of edaravone group and the high dose of edaravone group,18 rats in each group.Their lung function,serum antioxidant factors,inflammatory factors in bronchoalveolar lavage fluid and metalloproteinase in lung tissues were detected 4 weeks after modeling.Results The pulmonary function testing showed that compared with the blank group,the levels of f and RI were significantly higher,and Cdyn and PIF levels were significantly lower in the COPD model group(P<0.05).Compared with the COPD model group,the level of RI was significantly lower,the levels of Cdyn and PIF were significantly higher in the low dose edaravone group,and the levels of f and RI were significantly lower,the levels of Cdyn and PIF were obviously higher in the high dose edaravone group.Compared with the low dose edaravone group,the level of Cdyn in the high dose edaravone group was obviously increased(P<0.05).Plasma antioxidant test results showed that compared with the blank group,the levels of MDA and SOD in the COPD model group were increased significantly(P<0.05).Compared with the COPD model group,the level of MDA in the low dose edaravone group and the high dose edaravone groups were significantly lower(P<0.05).The results of bronchoalveolar lavage fluid detection showed that compared with the blank group,the levels of WBC and TNF-αin the COPD model group were increased significantly(P<0.05).Compared with the COPD model group,the levels of WBC and TNF-αin the low dose edaravone group and the high dose edaravone group were significantly lower(P<0.05).Compared with the low dose edaravone group,the levels of WBC and TNF-αin the high dose edaravone group were significantly decreased(P<0.05).The lung tissue test showed that compared with the blank group,the expression of MMP-9,MMP-12,Caspase-12 and CHOP in the COPD model group were obviously increased(P<0.05).Compared with the COPD model group,the expression of MMP-9,MMP-12,Caspase-12 and CHOP in the low dose edaravone group and the high dose edaravone group were decreased significantly(P<0.05).Compared with the low dose edaravone group,the expression of MMP-9,MMP-12,Caspase-12 and CHOP in the high dose edaravone group were decreased significantly(P<0.05).Conclusion Edaravone can improve the anti-oxidation ability,reduce the release of inflammatory factors and aggregation,and improve protease regulation to delay the clinical pathological progress of COPD.